Maxvax Biotech held a grand commencement ceremony for the "Innovative Vaccine Production Platform Project" of Shanghai Maxvax Biotech, a wholly-owned subsidiary of Chengdu Maxvax Biotech, in the Lingang New Area of Shanghai on June 27, 2022. Leaders of Shanghai Lingang Fengxian Economic Development Company (Chairman Mr. Linkun Zou, Assistant General Manager Ms. Aiying Ding, and Deputy Director of Project Promotion Department Mr. Jie Duan) and leaders of Maxvax  (Deputy General Manager Mr. Yi Jin and Mr. Yichun Dong), and other leaders and partners attended the event.

Mr. Jin, Deputy General Manager of Maxvax Biotech, delivered a speech at the opening ceremony. He extended a sincere welcome on behalf of Maxvax Biotech to the guests at the ceremony. He believed the "Innovative Vaccine Production Platform" would be one of the core platforms for the commercialization of the company's future R&D achievements. It would help facilitate the production of phase III clinical products for the company's two innovative vaccines which had been approved for clinical trial, and lay a solid foundation for their commercial production. Afterwards, the contractor gave a solemn pledge in terms of construction standards and process management, promising that the project shall be completed on schedule, and that the quality shall meet the requirements upon project acceptance.

Mr. Zou, Chairman of Shanghai Lingang Fengxian Economic Development Company, delivered a speech at the commencement ceremony. He highly praised Maxvax Biotech's world-leading technology and vaccine products that had filled the blank in the Chinese market， and stressed the key role of Life Science Blue Bay, a life science and technology industrial park in the area, in the layout of Shanghai’s biopharmaceutical industry. He also emphasized the ecological status of the park in the health industry, with more and more companies from both upstream and downstream of the industrial chain increasingly amassed there. The ceremony was successfully concluded as Mr. Zou announced the commencement of Maxvax Biotech's Innovative Vaccine Production Platform Project, with anticipation that the platform be successfully constructed and put into use on schedule.

Shanghai Maxvax Biotechnology, situated in Lingang New Area, is a wholly-owned subsidiary of Maxvax Biotech. Maxvax Biotech's "Innovative Vaccine Production Platform" is currently under construction in the park and a land of about 8.5 acres has been planned for its Phase I project, which will constitute the company's innovative vaccine R&D and industrialization base.